Paired box 2 promotes progression of endometrial cancer via regulating cell cycle pathway
暂无分享,去创建一个
K. Wong | W. Feng | N. Jia | X. Tao | Jieyu Wang | Qin Li | Chao Wang | Tianjiao Lyv
[1] G. Ning,et al. Digital quantification of precursor frequency in the fallopian tube and its significance , 2012, Modern Pathology.
[2] A. Krasinskas,et al. Is PAX2 a Reliable Marker in Differentiating Diffuse Malignant Mesotheliomas of Peritoneum From Serous Carcinomas of Müllerian Origin? , 2012, Applied immunohistochemistry & molecular morphology : AIMM.
[3] G. Ning,et al. PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer , 2012, Modern Pathology.
[4] S. Taşkın,et al. Expression pattern of PAX2 in hyperplastic and malignant endometrium , 2012, Archives of Gynecology and Obstetrics.
[5] C. Lacombe,et al. PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype , 2011, Molecular Cancer.
[6] M. Roh,et al. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Müllerian carcinoma in effusions , 2011, Diagnostic cytopathology.
[7] Jessica L. Davis,et al. PAX2 Expression in Wilms Tumors and Other Childhood Neoplasms , 2011, The American journal of surgical pathology.
[8] P. Cheng,et al. RNA interference of pax2 inhibits growth of transplanted human endometrial cancer cells in nude mice , 2011, Chinese journal of cancer.
[9] E-hu Liu,et al. 2ME and 2OHE2 exhibit growth inhibitory effects and cell cycle arrest at G2/M in RL95-2 human endometrial cancer cells through activation of p53 and Chk1 , 2011, Molecular and Cellular Biochemistry.
[10] J. McKenney,et al. The Utility of Pax-2 and Renal Cell Carcinoma Marker Immunohistochemistry in Distinguishing Papillary Renal Cell Carcinoma From Nonrenal Cell Neoplasms With Papillary Features , 2010, Applied immunohistochemistry & molecular morphology : AIMM.
[11] G. Ning,et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube , 2010, The Journal of pathology.
[12] D. Neuberg,et al. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. , 2010, Cancer research.
[13] L. Truong,et al. PAX-2 Expression in Non-neoplastic, Primary Neoplastic, and Metastatic Neoplastic Tissue: A Comprehensive Immunohistochemical Study , 2010, Applied immunohistochemistry & molecular morphology : AIMM.
[14] S. Bose,et al. PAX2 oncogene negatively regulates the expression of the host defense peptide human beta defensin-1 in prostate cancer. , 2009, Molecular immunology.
[15] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[16] M. Amin,et al. Diagnostic Implications of Transcription Factor Pax 2 Protein and Transmembrane Enzyme Complex Carbonic Anhydrase IX Immunoreactivity in Adult Renal Epithelial Neoplasms , 2009, The American journal of surgical pathology.
[17] P. Grundy,et al. WNT5A is regulated by PAX2 and may be involved in blastemal predominant Wilms tumorigenesis. , 2008, Neoplasia.
[18] Mirana Ramialison,et al. Rapid identification of PAX2/5/8 direct downstream targets in the otic vesicle by combinatorial use of bioinformatics tools , 2008, Genome Biology.
[19] M. Bouchard,et al. A novel gene downstream of Pax2 is overexpressed in Wilms' tumors and encodes for a Calcineurin A binding protein , 2008 .
[20] Pierre Dubus,et al. Cdk1 is sufficient to drive the mammalian cell cycle , 2007, Nature.
[21] A. Borczuk,et al. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin? , 2007, Modern Pathology.
[22] Andre C. Eaddy,et al. Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status. , 2007, Cancer letters.
[23] P. Ganly,et al. Translocation (5;10)(q22;q24) in a case of acute lymphoblastic leukemia. , 2006, Cancer genetics and cytogenetics.
[24] J. Carl Barrett,et al. Prediction of Lymph Node Metastasis in Patients with Endometrioid Endometrial Cancer Using Expression Microarray , 2006, Clinical Cancer Research.
[25] Luyang Sun,et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis , 2005, Nature.
[26] P. Kaldis,et al. Cdc2–cyclin E complexes regulate the G1/S phase transition , 2005, Nature Cell Biology.
[27] P. Cassoni,et al. Role of Pax2 in Apoptosis Resistance and Proinvasive Phenotype of Kaposi's Sarcoma Cells* , 2004, Journal of Biological Chemistry.
[28] G. Dressler,et al. The Secreted Frizzled Related Protein 2 (SFRP2) Gene Is a Target of the Pax2 Transcription Factor* , 2003, Journal of Biological Chemistry.
[29] M. Eccles,et al. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival , 2003, Oncogene.
[30] G. Dressler,et al. Regulation of ureteric bud outgrowth by Pax2-dependent activation of the glial derived neurotrophic factor gene. , 2001, Development.
[31] H. Cunliffe,et al. Differential regulation of the human Wilms tumour suppressor gene (WT1) promoter by two isoforms of PAX2 , 1997, Oncogene.
[32] J. Pelletier,et al. The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1). , 1996, Oncogene.